View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Aug. 30 (HealthDay News) -- Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.
To determine whether metformin use in type 2 diabetes is associated with the incidence of lung cancer, Brielan B. Smiechowski, from the Jewish General Hospital in Montreal, and colleagues analyzed data from 115,923 patients with type 2 diabetes newly treated with oral hypoglycemic agents.
The researchers found that 1,061 patients were diagnosed with lung cancer during follow-up. Based on matching each lung cancer case with up to 10 matched control subjects, metformin had no effect on the lung cancer rate (rate ratio, 0.94). Smoking status had no effect. No dose-response was noted based on number of prescriptions received, cumulative duration of use, and cumulative dose.
"Metformin use is not associated with a decreased risk of lung cancer in patients with type 2 diabetes," Smiechowski and colleagues conclude. "The decreased risk reported in other observational studies is likely due to bias from methodological shortcomings."
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top